Vanda Reports Strong Phase III Data For Sleep Disorder Candidate In Chronic Insomnia
This article was originally published in The Pink Sheet Daily
Executive Summary
VEC-162 also being tested in transient insomnia, circadian rhythm sleep disorders and mood disorders.
You may also be interested in...
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
FDA requests additional Phase III comparative study and safety data for iloperidone.
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
FDA requests additional Phase III comparative study and safety data for iloperidone.
Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.